EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study

Alexander Rombauts, Marta Bodro, Victor Daniel Gumucio, Irene Carbonell, Àlex Favà, Laura Lladó, José González-Costello, Federico Oppenheimer, María Ángeles Castel-Lavilla, Oscar Len, Ester Marquez-Algaba, Xavier Nuvials-Casals und 4 weitere

Frontiers in Cellular and Infection Microbiology · 27.04.2023 · 13

DOI: 10.3389/fcimb.2023.1165236 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 27.04.2023. Verfasst von Alexander Rombauts und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. Hauptthemen laut MEDLINE: COVID-19, Organ Transplantation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

COVID-19-associated pulmonary aspergillosis (CAPA) has emerged as a frequent complication in the intensive care unit (ICU). However, little is known about this life-threatening fungal superinfection in solid organ transplant recipients (SOTRs), including whether targeted anti-mold prophylaxis might be justified in this immunosuppressed population. We performed a multicentric observational retrospective study of all consecutive ICU-admitted COVID-19 SOTRs between August 1, 2020 and December 31, 2021. SOTRs receiving antifungal prophylaxis with nebulized amphotericin-B were compared with those without prophylaxis. CAPA was defined according the ECMM/ISHAM criteria. Sixty-four SOTRs were admitted to ICU for COVID-19 during the study period. One patient received antifungal prophylaxis with isavuconazole and was excluded from the analysis. Of the remaining 63 SOTRs, nineteen (30.2%) received anti-mold prophylaxis with nebulized amphotericin-B. Ten SOTRs who did not receive prophylaxis developed pulmonary mold infections (nine CAPA and one mucormycosis) compared with one who received nebulized amphotericin-B (22.7% vs 5.3%; risk ratio 0.23; 95%CI 0.032-1.68), but with no differences in survival. No severe adverse events related to nebulized amphotericin-B were recorded. SOTRs admitted to ICU with COVID-19 are at high risk for CAPA. However, nebulized amphotericin-B is safe and might reduce the incidence of CAPA in this high-risk population. A randomized clinical trial to confirm these findings is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Organ TransplantationHumansAmphotericin BAntifungal AgentsRetrospective Studies

Stichwörter der Autor:innen

AspergillosisAspergillus spp.CAPACOVID-19SARS-CoV-2amphotericin-Bprophylaxissolid-organ transplant recipients

Substanzen

Amphotericin BAntifungal Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Department of Infectious Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Department of Intensive Care Medicine, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Renal Transplant Unit, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Liver Transplant Unit, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Heart Transplant Unit, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Rombauts, A., Bodro, M., Daniel Gumucio, V., Carbonell, I., Favà, À., Lladó, L., González-Costello, J., Oppenheimer, F., Castel-Lavilla, M. Á., Len, O., Marquez-Algaba, E., Nuvials-Casals, X., Martínez González, D., Lacasa, J. S., Carratalà, J., & Sabé, N. (2023). Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1165236

Vancouver

Rombauts A, Bodro M, Daniel Gumucio V, Carbonell I, Favà À, Lladó L, et al. Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1165236

BibTeX
@article{Rombauts2023,
  author = {Rombauts, Alexander and Bodro, Marta and Daniel Gumucio, Victor and Carbonell, Irene and Favà, Àlex and Lladó, Laura and González-Costello, José and Oppenheimer, Federico and Castel-Lavilla, María Ángeles and Len, Oscar and Marquez-Algaba, Ester and Nuvials-Casals, Xavier and Martínez González, Daniel and Lacasa, Judith Sacanell and Carratalà, Jordi and Sabé, Nuría},
  title = {Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fcimb.2023.1165236}
}
Kostenlos starten →